gliclazide has been researched along with Hyperglycemia in 18 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was hypothesized to investigate the hepatoprotective nature of resveratrol in averting hyperglycemia-mediated oxidative stress by measuring extent of oxidant stress and levels of proinflammatory cytokines and antioxidant competence in the hepatic tissues of streptozotocin-nicotinamide-induced diabetic rats." | 7.76 | Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. ( Palsamy, P; Sivakumar, S; Subramanian, S, 2010) |
| "The present study was hypothesized to investigate the hepatoprotective nature of resveratrol in averting hyperglycemia-mediated oxidative stress by measuring extent of oxidant stress and levels of proinflammatory cytokines and antioxidant competence in the hepatic tissues of streptozotocin-nicotinamide-induced diabetic rats." | 3.76 | Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. ( Palsamy, P; Sivakumar, S; Subramanian, S, 2010) |
| "In conclusion, in long-standing type 2 diabetes the acute administration of gliclazide significantly enhances second phase insulin release at a moderately elevated blood glucose level." | 2.70 | Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus. ( Ligtenberg, JJ; Reitsma, WD; van Haeften, TW, 2001) |
| " Physiological and treatment-related factors were evaluated as potential influential covariates using a population pharmacokinetic modeling approach (NONMEM version 7." | 1.62 | Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats. ( Adiwidjaja, J; Sasongko, L, 2021) |
| "Treatment with empagliflozin showed a significant amelioration of behavioral/neurological functions and histopathological changes observed in brain tissues of hyperglycemic rats subjected to cerebral I/R injury." | 1.56 | Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. ( Abdel-Latif, RG; Amin, EF; Rifaai, RA, 2020) |
| "Erythroderma is generalized exfoliative dermatitis, which involves more than 90% of the patient's skin." | 1.40 | Erythroderma secondary to gliclazide: a case report. ( Kacar, SD; Karaca, S; Ozuguz, P; Ozuguz, U; Tokyol, C, 2014) |
| " Pharmacokinetic and pharmacodynamic parameters were examined in the interval of 30 to 180 min after p." | 1.34 | Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats. ( Kvetina, J; Pastera, J; Polásková, A; Prazáková, M; Stetinová, V, 2007) |
| "The onset of Type 2 diabetes is insidious and is usually recognized only 5-12 years after hyperglycaemia develops." | 1.30 | Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection. ( Muggeo, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Amin, EF | 1 |
| Rifaai, RA | 1 |
| Abdel-Latif, RG | 1 |
| Adiwidjaja, J | 1 |
| Sasongko, L | 1 |
| Ozuguz, P | 1 |
| Kacar, SD | 1 |
| Ozuguz, U | 1 |
| Karaca, S | 1 |
| Tokyol, C | 1 |
| Chen, R | 1 |
| Lopes, J | 1 |
| Del Guerra, S | 1 |
| D'Aleo, V | 1 |
| Lupi, R | 1 |
| Masini, M | 1 |
| Bugliani, M | 1 |
| Boggi, U | 1 |
| Filipponi, F | 1 |
| Marchetti, P | 1 |
| Palsamy, P | 1 |
| Sivakumar, S | 1 |
| Subramanian, S | 1 |
| Awasthi, R | 1 |
| Kulkarni, GT | 1 |
| Pearson, ER | 1 |
| Starkey, BJ | 1 |
| Powell, RJ | 1 |
| Gribble, FM | 1 |
| Clark, PM | 1 |
| Hattersley, AT | 1 |
| Ozer, F | 1 |
| Mutlu, A | 1 |
| Ozkayran, T | 1 |
| Satyanarayana, S | 1 |
| Sekhar, JR | 1 |
| Kumar, KE | 1 |
| Shannika, LB | 1 |
| Rajanna, B | 1 |
| Rajanna, S | 1 |
| Stetinová, V | 1 |
| Kvetina, J | 1 |
| Pastera, J | 1 |
| Polásková, A | 1 |
| Prazáková, M | 1 |
| Page, RC | 1 |
| Harnden, KE | 1 |
| Walravens, NK | 1 |
| Onslow, C | 1 |
| Sutton, P | 1 |
| Levy, JC | 1 |
| Hockaday, DT | 1 |
| Turner, RC | 3 |
| Matthews, DR | 1 |
| Boland, O | 1 |
| Hammersley, MS | 2 |
| Meyer, LC | 1 |
| Morris, RJ | 2 |
| Manley, SE | 1 |
| Holman, RR | 2 |
| Karunakaran, S | 1 |
| Bardini, G | 1 |
| Mannucci, E | 1 |
| Rotella, CM | 1 |
| Muggeo, M | 1 |
| Ligtenberg, JJ | 1 |
| Reitsma, WD | 1 |
| van Haeften, TW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Pharmacogenetics to Improve Treatment in Early-onset Diabetes[NCT01238380] | 1,916 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for gliclazide and Hyperglycemia
| Article | Year |
|---|---|
Genetic cause of hyperglycaemia and response to treatment in diabetes.
Topics: Adult; Aged; ATP-Binding Cassette Transporters; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, | 2003 |
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
Topics: Adolescent; Adult; Body Weight; Cardiovascular Diseases; Double-Blind Method; Exercise Therapy; Glic | 1993 |
The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
Topics: Aged; Arginine; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Respon | 1997 |
The Fasting Hyperglycaemia Study: I. Subject identification and recruitment for a non-insulin-dependent diabetes prevention trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Fructosamin | 1997 |
The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; England; Fasting; Female; France; Gliclazide; | 1997 |
Effect of different pharmacological formulations of gliclazide on postprandial hyperglycaemia.
Topics: Blood Glucose; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyp | 1998 |
Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.
Topics: Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; | 2001 |
11 other studies available for gliclazide and Hyperglycemia
| Article | Year |
|---|---|
Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Disease Models, Animal; Gliclazide; Glucosides; Hyperglyce | 2020 |
Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats.
Topics: Animals; Biological Availability; Blood Glucose; Gliclazide; Herb-Drug Interactions; Hyperglycemia; | 2021 |
Erythroderma secondary to gliclazide: a case report.
Topics: Aged; Dermatitis, Exfoliative; Drug Eruptions; Female; Gliclazide; Humans; Hyperglycemia; Hypoglycem | 2014 |
Hyperglycaemia secondary to mirtazapine therapy in a 37-year-old man.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Therapy, Combination; Glic | 2008 |
Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide.
Topics: Aged; Analysis of Variance; Cells, Cultured; Female; Gliclazide; Glucose; Glyburide; Homeodomain Pro | 2009 |
Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats.
Topics: Animals; Antioxidants; Cytokines; Diabetes Mellitus, Experimental; Gliclazide; Hepatocytes; Hypergly | 2010 |
Development of novel gastroretentive floating particulate drug delivery system of gliclazide.
Topics: Alginates; Animals; Blood Glucose; Calcium Carbonate; Drug Carriers; Gastrointestinal Tract; Gelatin | 2012 |
Reflex epilepsy and non-ketotic hyperglycemia.
Topics: Blood Glucose; Electroencephalography; Epilepsy, Reflex; Female; Gliclazide; Humans; Hyperglycemia; | 2003 |
Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Th | 2006 |
Gliclazide: pharmacokinetic-pharmacodynamic relationships in rats.
Topics: Administration, Oral; Alloxan; Animals; Area Under Curve; Blood Glucose; Chromatography, High Pressu | 2007 |
Accelerated complications in Type 2 diabetes mellitus: the need for greater awareness and earlier detection.
Topics: Amputation, Surgical; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic | 1998 |